These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43 related articles for article (PubMed ID: 34313913)
1. Case report: BTK inhibitors is effective in type II mixed cryoglobulinemia with wild-type MyD88. Xu M; Xu Y; Yuan L; Shang D; Chen R; Liu S; Li Y; Liu A; Liu R; Wang Q; Ding T; Xie Q; Hao CM Front Immunol; 2024; 15():1390958. PubMed ID: 38765016 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock. Minotti G Blood Adv; 2024 Jul; 8(14):3810-3812. PubMed ID: 38696711 [No Abstract] [Full Text] [Related]
4. All-in-one Hangzhou Protocol: killing four birds with one stone. Wang H; Qiu S; Mohty M Cell Res; 2024 May; ():. PubMed ID: 38822121 [No Abstract] [Full Text] [Related]
5. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996 [TBL] [Abstract][Full Text] [Related]
7. Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma. Claves F; Siest R; Lefebvre C; Valmary-Degano S; Carras S J Clin Immunol; 2021 Aug; 41(6):1380-1383. PubMed ID: 33871787 [No Abstract] [Full Text] [Related]
8. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Jalink M; Berentsen S; Castillo JJ; Treon SP; Cruijsen M; Fattizzo B; Cassin R; Fotiou D; Kastritis E; De Haas M; Oosten LEM; Frederiksen H; Patriarca A; D'Sa S; Vos JMI Blood; 2021 Nov; 138(20):2002-2005. PubMed ID: 34293088 [No Abstract] [Full Text] [Related]
9. Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome. Huang Y; Wang Y; Yu F; Mao X; Wang B; Li J; Li L Front Immunol; 2022; 13():894464. PubMed ID: 35514998 [TBL] [Abstract][Full Text] [Related]
10. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia. Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M Front Immunol; 2021; 12():766272. PubMed ID: 34912339 [TBL] [Abstract][Full Text] [Related]
11. Killing Two Birds with One Stone: the Therapeutic Role of Ibrutinib in Schnitzler Syndrome. Wang C J Clin Immunol; 2021 Oct; 41(7):1706-1707. PubMed ID: 34313913 [No Abstract] [Full Text] [Related]